Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 study of crizotinib (PF-02341066) in MET exon 14–positive NSCLC
jRCT2080223635Phase 1Completed
- Sponsor
- Pfizer
- Start
- Aug 2017
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of crizotinib in non-small cell lung cancer (NSCLC), sponsored by Pfizer. Primary endpoints: Safety and tolerability of PF-02341066, Pharmacokinetics of PF-02341066 and 1 more. Started Aug 2017; status: completed.
02
Drugs
crizotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2080223635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080223635.